A major impediment to more effective cancer treatment is the ability of tumors to acquire resistance to cytotoxic and cytostatic therapeutics, a development that contributes to treatment failures exceeding 90% in patients with metastatic carcinomas 1 . Efforts focused on circumventing cellular survival mechanisms after chemotherapy have defined systems that modulate the import, export or metabolism of drugs by tumor cells [2] [3] [4] [5] [6] . Enhanced damage repair and modifications to apoptotic and senescence programs also contribute to de novo or acquired tolerance to anti-neoplastic treatments 3, 7, 8 . In addition, the finding that ex vivo assays of sensitivity to chemotherapy do not accurately predict responses in vivo indicate that tumor microenvironments also contribute substantially to cellular viability after toxic insults [9] [10] [11] . For example, cell adhesion to matrix molecules can affect life and death decisions in tumor cells responding to damage [12] [13] [14] . Further, the spatial organization of tumors relative to the vasculature establishes gradients of drug concentration, oxygenation, acidity and states of cell proliferation, each of which may substantially influence cell survival and the subsequent tumor repopulation kinetics 15, 16 .
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Most cytotoxic agents selectively target cancers by exploiting differential tumor cell characteristics, such as high proliferation rates, hypoxia and genome instability, resulting in a favorable therapeutic index. However, cancer therapies also affect benign cells and can disrupt the normal function and physiology of tissues and organs. To avoid host lethality, most anticancer regimens do not rely on single overwhelming treatment doses: both radiation and chemotherapy are administered at intervals to allow the recovery of vital normal cell types. However, gaps between treatment cycles also allow tumor cells to recover, activate and exploit survival mechanisms and resist subsequent therapeutic insults.
Here we tested the hypothesis that treatment-associated DNA damage responses in benign cells comprising the tumor microenvironment promote therapy resistance and subsequent tumor progression. We provide in vivo evidence of treatment-induced alterations in tumor stroma that include the expression of a diverse spectrum of secreted cytokines and growth factors. Among these, we show that WNT16B is activated in fibroblasts through NF-κB and promotes an epithelial to mesenchymal transition (EMT) in neoplastic prostate epithelium through paracrine signaling. Further, WNT16B, acting in a cell nonautonomous manner, promotes the survival of cancer cells after cytotoxic therapy. We conclude that approaches targeting constituents of the tumor microenvironment in conjunction with conventional cancer therapeutics may enhance treatment responses.
RESULTS

Therapy induces damage responses in tumor microenvironments
To assess for treatment-induced damage responses in benign cells comprising the tumor microenvironment, we examined tissues collected before and after chemotherapy exposure in men with prostate cancer enrolled in a neoadjuvant clinical trial combining the genotoxic drug mitoxantrone (MIT) and the microtubule poison docetaxel (DOC) (Fig. 1a) 17, 18 . After chemotherapy, we found evidence of DNA damage in fibroblasts and smooth muscle cells comprising the prostate stroma, as determined by the phosphorylation of histone H2AX on Ser139 (γ-H2AX) (Fig. 1b) . To ascertain the molecular consequences of DNA damage in benign cells, we treated primary prostate fibroblasts (PSC27 cells) with MIT, bleomycin (BLEO), hydrogen peroxide (H 2 O 2 ) or gamma radiation (RAD), each of which substantially increased the number of γ-H2AX foci (Supplementary Fig. 1a,b) . We used whole-genome microarrays to quantify transcripts in PSC27 cells and determined that the levels of 727 and 329 mRNAs were commonly increased and decreased, respectively (false discovery rate of 0.1%), as a result of these genotoxic exposures (Supplementary Fig. 1c) . To focus our studies on those factors with the clear potential for paracrine effects on tumor cells, we evaluated genes with at least 3.5-fold elevated expression after genotoxic treatments that encode extracellular proteins, here collectively termed the DNA damage secretory program (DDSP) (Fig. 1c) . Consistent with previous studies, transcripts encoding matrix metalloproteinases such as MMP1, chemokines such as CXCL3 and peptide growth factors such as amphiregulin were substantially elevated in PSC27 fibroblasts after genotoxic damage 19, 20 . Notably, the expression of WNT16B increased between eightfold and 64-fold as a result of these treatments (P < 0.005) (Fig. 1c,d) .
Wnt family members participate in well-described mesenchymal and epithelial signaling events that span developmental biology, stem cell functions and neoplasia 21 . Though little information links Wnt signaling to DNA damage responses, a previous study reported WNT16B overexpression in the context of stress-and oncogeneinduced senescence 22 . We confirmed that DNA damage increased WNT16B protein expression and found elevated amounts of extracellular WNT16B in conditioned medium from prostate fibroblasts after chemotherapy or radiation (Fig. 1e,f) . Transcripts encoding other Wnt family members were not substantially altered in the prostate fibroblasts we studied here (Fig. 1g) . In contrast to the WNT16B responses in fibroblasts, we observed little induction of WNT16B expression in epithelial cells (Fig. 1h) .
We next sought to confirm that expression of WNT16B is induced by genotoxic therapy in vivo. We used laser-capture microdissection to separately isolate stroma and epithelium and determined IL8   MMP1   MMP10  ENPP5  EREG  BMP6  ANGPTL4  CSGALNACT  CCL26  AREG  ANGPT1  CCK  THBD  CXCL14  NOV  GAL  NPPC  FAM150B  CST1  GDNF  MUCL1  NPTX2  TMEM155  EDN1  PSG9  ADAMTS3  CD24  PPBP  CXCL3  MMP3  CST2  PSG8  PCOLCE2  PSG7  TNFSF15  C17orf67  CALCA  FGF18   BMP2  MATN3  TFPI  SERPINI1  TNFRSF25  IL23A   MMP12 npg by quantitative RT-PCR (qRT-PCR) that the number of WNT16B transcripts increased by approximately sixfold in prostate stroma after chemotherapy (P < 0.01) ( Fig. 2a and Supplementary Fig. 1d ). The expression of other genes known to respond to DNA damage, including CDKN2A (also known as p16), CDKN1A (also known as p21) and IL8, also increased in response to chemotherapy in prostate stroma (Fig. 2a) 20, 23 . We next confirmed induction of WNT16B protein expression by immunohistochemistry. Compared to untreated prostate tissue, WNT16B protein was substantially and significantly increased after chemotherapy in the periglandular stroma, which included fibroblasts and smooth muscle cells (P < 0.01) (Fig. 2b,c) .
In contrast, we observed very limited WNT16B expression in benign or neoplastic epithelium, and mRNAs encoding other Wnt family proteins were not substantially altered in prostate stroma ( Supplementary Fig. 1d,e) . We confirmed these findings in breast and ovarian carcinomas, two other malignancies commonly treated with cytotoxic chemotherapy. Genotoxic treatments induced the expression of WNT16B protein in primary human fibroblasts isolated directly from breast and ovarian tissues and in the prostates, breasts and ovaries of mice treated with MIT ( Supplementary Fig. 2a-d) . WNT16B protein expression was significantly elevated in the stroma of human breast and ovarian cancers treated with neoadjuvant chemotherapy compared with tumors from patients that did not receive treatment (P < 0.001) (Fig. 2) . Notably, in each of the tumor types evaluated, a range of absent to robust WNT16B expression was evident. Because responses to chemotherapy also varied, we evaluated whether WNT16B expression was associated with clinical outcome. In patients with prostate cancer treated with neoadjuvant chemotherapy, higher WNT16B immunoreactivity in prostate stroma after treatment was associated with a significantly greater likelihood of cancer recurrence (P = 0.04) (Fig. 2d) . We next sought to determine the mechanism(s) by which WNT16B could contribute to treatment failure.
WNT16B promotes cancer cell proliferation and invasion
Members of the Wnt family influence cellular phenotypes through β-catenin-dependent and -independent pathways 21 . We generated a prostate fibroblast cell strain with stable expression of WNT16B The P values were calculated by Student's t test. (b) IHC assessment of prostate stromal WNT16B expression in prostatectomy tissue samples from men with prostate cancer who were either untreated (n = 30) or treated with chemotherapy (n = 50). Patients were assigned to four categories based on their stromal WNT16B staining: 0, no expression; 1, faint or equivocal expression; 2, moderate expression; 3, intense reactivity. P < 0.0001 by ANOVA. (c) Representative example of intense WNT16B expression in prostate stroma after in vivo exposure to MIT and DOC. The black arrows denote areas of the stroma with fibroblasts and smooth muscle. Note the minimal WNT16B reactivity in the epithelium (gray arrows). Scale bars, 50 µm. (d) KaplanMeier plot of biochemical (prostate-specific antigen) relapse-free survival based on the expression of WNT16B in prostate stroma after exposure to MIT and DOC chemotherapy (P = 0.04 by log-rank test comparing WNT16B < 1 with WNT16B ≥ 2 survival distributions). DFI, disease-free interval from surgery. (e,f) WNT16B staining of breast (e) and ovarian (f) carcinoma from patients receiving neoadjuvant chemotherapy or no treatment before surgical resection. Staining is recorded on a 4-point scale: 0, no expression; 1, faint or equivocal expression; 2, moderate expression; 3, intense reactivity. Scale bars, 50 µm. The P values were calculated by ANOVA. npg (PSC27 WNT16B ) and fibroblast strains that expressed shRNAs specific to WNT16B (shRNA WNT16B ), which blocked the induction of WNT16B expression by RAD and MIT ( Supplementary Fig. 3a,b) . PSC27 WNT16B -conditioned medium significantly enhanced prostate cancer cell growth (P < 0.01) (Fig. 3a) and increased cellular migration and invasion (P < 0.05) compared to conditioned medium from PSC27 vector controls (PSC27 C ) ( Fig. 3b and Supplementary  Fig. 3c,d ), confirming that WNT16B can promote phenotypic changes in tumor cells through paracrine mechanisms.
The DDSP comprises a diverse spectrum of secreted proteins with the potential to alter the phenotypes of neighboring cells (Fig. 1c) . We next sought to determine to what extent WNT16B is responsible for such effects in the context of the amalgam of factors induced by DNA damage. Conditioned medium from irradiated PSC27 fibroblasts (PSC27-RAD), representing the full DDSP, increased the proliferation (between 1.5-fold and twofold, P < 0.05) and invasiveness (between threefold and fourfold, P < 0.05) of neoplastic epithelial cells compared to conditioned medium from untreated PSC27 fibroblasts (Fig. 3c,d ). Compared to irradiated PSC27 cells expressing control shRNAs, conditioned medium from PSC27-RAD + shRNA WNT16B fibroblasts reduced these responses to the full DDSP by between 15% and 35%, depending on the cell line (P < 0.05) (Fig. 3c,d) .
To investigate the in vivo consequences of WNT16B expression in the tumor microenvironment, we combined nontumorigenic BPH1 or tumorigenic PC3 cells with PSC27 WNT16B (BPH1+PSC27 WNT16B and PC3+PSC27 WNT16B , respectively) or control PSC27 (BPH1+PSC27 C and PC3+PSC27 C , respectively) fibroblasts and implanted the recombinants under the renal capsule of recipient mice (Fig. 3e) . At 8 weeks after implantation, BPH1+PSC27 WNT16B grafts were larger than BPH1+PSC27 C grafts (~200 mm 3 compared to ~10 mm 3 , respectively; P < 0.001) (Supplementary Fig. 3e ). PC3+PSC27 WNT16B recombinants generated very large poorly differentiated and invasive tumors with an average size of 500 mm 3 , which was substantially larger than any of the control tumors (P < 0.001) (Fig. 3f and Supplementary Fig. 3f) .
In vivo, PC3 cells combined with PSC27-RAD cells expressing the full fibroblast DDSP resulted in substantially larger tumors than PC3 cells combined with untreated PSC27 control fibroblasts (P < 0.001) (Fig. 3g) . Reducing the fibroblast contribution of WNT16B attenuated the PSC27-RAD effects: grafts of PC3+PSC27-RAD averaged 380 mm 3 , whereas PC3 cells combined with PSC27-RAD+shRNA WNT16B averaged 280 mm 3 , a ~25% reduction in tumor size when fibroblast WNT16B was suppressed (P < 0.02) (Fig. 3g) .
Taken together, these findings show that paracrine WNT16B activity can promote tumor growth in vivo and accounts for a substantial component of the full DDSP effect on neoplastic epithelium.
WNT16B signals through b-catenin and induces an EMT
Having established that WNT16B can promote tumor growth through paracrine signaling, we next sought to determine the mechanism(s) by which it does so. PSC27 WNT16B -conditioned medium activated . Epithelial cells were exposed to conditioned medium (CM) from PSC27 prostate fibroblasts expressing WNT16B (PSC27 WNT16B ) or control vector (PSC27 C ). Data are mean ± s.e.m. of triplicates, and P values were determined by ANOVA followed by t test. (b) qRT-PCR assessment of the expression of β-catenin target genes in prostate cancer cell lines (BPH1, M12 and PC3) before and 72 h after exposure to PSC27 WNT16B -conditioned medium. Data represent the mean ± s.e.m. fold change after as compared to before exposure for three replicates. (c) Expression of β-catenin target genes in human prostate cancers in vivo after neoadjuvant treatment with MIT and DOC. Log2 transcript amounts in carcinoma cells after and before chemotherapy are shown in relation to low (blue) or high (red) WNT16B expression in the prostate stroma. Each data point represents an individual patient; n = 8 patients. Horizontal bars are group means. *P < 0.05, **P < 0.01 by ANOVA followed by t test. (d) The β-catenin pathway inhibitor XAV939 suppresses the proliferation of prostate cancer cells in response to PSC27 WNT16B CM and attenuates the response to the full DDSP in PSC27-RAD-conditioned medium. Cell numbers were determined 72 h after treatment. (e) Quantification of transcripts in neoplastic prostate epithelial cells encoding proteins associated with a phenotype of EMT. Measurements are from epithelial cells exposed to control media (DMEM), media conditioned by PSC27 fibroblasts (PSC27 C ) or PSC27 fibroblasts expressing WNT16B (PSC27 WNT16B ). E-cad, E-cadherin; N-cad, N-cadherin. (f) Analysis of EMT-associated protein expression by western blot. M12 or PC3 cells were exposed to control media, media conditioned by PSC27 fibroblasts (PSC27 C ), PSC27 fibroblasts expressing WNT16B (PSC27 WNT16B ) or PSC27 fibroblasts expressing WNT16B and shRNA targeting WNT16B (PSC27 shRNA-WNT16B ). (g) Chromatin immunoprecipitation assays identified NF-κB binding sites within the proximal promoter of the WNT16 gene. PCR reaction products from Mock (no DNA loading), NF-κB immunoprecipitation, input control DNA and no antibody (Ab) control before treatment (Pre) and after irradiation (Rad). p1, p2 and p3 indicate primer pairs corresponding to putative NF-κB binding regions in WNT16, IL-6 and IL-8, respectively (see the Supplementary Methods for the primer sequences). (h) Analysis of WNT16B transcript expression by qRT-PCR in PSC27 prostate fibroblasts with (PSC27 IκBα ) or without (PSC27 C ) inhibition of NF-κB signaling before and after DNA-damaging exposures. (i) Inhibition of NF-κB signaling in fibroblasts responding to DNA damage attenuates the effect of the DDSP on tumor cell proliferation. Cell numbers were determined 72 h after RAD exposure to conditioned medium from fibroblasts with (PSC27 IκBα ) or without (PSC27 C ) inhibition of NF-κB signaling. Data in d, e, h and i are mean ± s.e.m. of triplicates, and P values were determined by ANOVA followed by t test.
npg canonical Wnt signaling in BPH1, PC3 and M12 prostate cancer cells, as measured by assays of β-catenin-mediated transcription through T cell factor/lymphoid enhancer binding factor (TCF/LEF) binding sites (Fig. 4a) . Known β-catenin target genes, including AXIN2 and MYC, were upregulated (approximately fivefold and over tenfold, respectively) after exposure to WNT16B-enriched conditioned medium (Fig. 4b) . In human prostate cancers treated with chemotherapy, β-catenin localized in the nucleus of tumor cells (Supplementary Fig. 4a ). We also found that β-catenin target genes were expressed more highly in tumors with elevated stromal WNT16B expression relative to those with low WNT16B expression (P < 0.05) (Fig. 4c) . To confirm that β-catenin signaling contributed to the epithelial phenotypes resulting from exposure to PSC27-RAD-conditioned medium, we treated prostate cancer cells with the tankyrase inhibitor XAV939, which stabilizes axin and inhibits β-catenin-mediated transcription 24 . XAV939 completely suppressed the proliferative and invasive responses induced by WNT16B and markedly attenuated the effects of the PSC27-RAD DDSP ( Fig. 4d and Supplementary Fig. 4b ). Wnt signaling is known to promote the acquisition of mesenchymal cell characteristics that can influence the migratory and invasive behavior of epithelial cells through an EMT [25] [26] [27] . Loss of CDH1 (also known as E-cadherin), the prototypic epithelial adhesion molecule in adherens junctions, and gain of CDH2 (also known as N-cadherin) expression are among the main hallmarks of an EMT 28, 29 . After exposure of PC3 cells to PSC27 WNT16B -conditioned medium, the number of E-cadherin transcripts decreased 64%, whereas the number of N-cadherin transcripts increased fourfold (P < 0.05). Similar alterations occurred in M12 and BPH1 cells (Fig. 4e,f) . Inhibiting β-catenin pathway signaling with XAV939 in epithelial cells blocked the WNT16B-induced EMT-associated gene expression ( Supplementary  Fig. 4c ). Exposure to PSC27 WNT16B -conditioned medium also promoted mesenchymal characteristics in MDA-MD-231 breast cancer and SKOV3 ovarian cancer cells (Supplementary Fig. 4d ).
Genotoxic stress induces WNT16B expression through NF-kB A key pathway linking DNA damage with apoptosis, senescence and DNA repair mechanisms involves activating the NF-κB complex 30, 31 . NF-κB is also pivotal in mediating the stress-associated induction of inflammatory networks, including the upregulation and secretion of interkeukin-6 (IL-6) and 32) . We therefore sought to determine whether DNA-damage-induced WNT16B expression is mediated by NF-κB. We identified NF-κB binding motifs in the WNT16B promoter region and confirmed their function using WNT16B promoter constructs. Compared to untreated cells, both RAD and tumor necrosis factor α (TNF-α), which are known NF-κB activators, induced WNT16B reporter activity (P < 0.01) ( Fig. 4g and Supplementary Fig. 5a-d) . We next generated PSC27 prostate fibroblasts with stable expression of a mutant nuclear factor of κ light polypeptide gene enhancer in B cells inhibitor, α (IκBα) (PSC27 IκBα ), npg which prevents IκB kinase (IKK)-dependent degradation of IκBα and thus attenuates NF-κB signaling. After irradiation of PSC27 cells, NF-κB translocated to the nucleus and induced NF-κB reporter activity >100-fold ( Supplementary Fig. 5d,e) . In comparison, the amount of nuclear NF-κB in PSC27 IκBα -RAD cells was markedly lower. The PSC27 IκBα cells with impaired NF-κB activation had a significant attenuation of induction of WNT16B expression after treatment with H 2 O 2 , BLEO or RAD (P < 0.05) (Fig. 4h) .
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MIT at IC 50 NS, P > 0.05 * P < 0.05 ** P < 0.01 We next determined whether suppressing fibroblast NF-κB signaling in response to DNA damage would attenuate the pro-proliferative effects of the PSC27-RAD DDSP. Whereas PSC27-RAD-conditioned medium promoted prostate epithelial cell proliferation, conditioned medium from PSC27 IκBα -RAD cells failed to do so (Fig. 4i) . These experiments identify WNT16B as a new member of the cellular genomic program that is regulated by NF-κB signaling in response to DNA damage.
Paracrine WNT16B attenuates the effect of cytotoxic therapy The preceding experiments suggested that in addition to tumorpromoting effects, paracrine-acting WNT16B may influence the responses of tumors to genotoxic cancer therapeutics. To evaluate this possibility, we studied MIT, a type 2 topoisomerase inhibitor that produces DNA strand breaks, leading to growth arrest, senescence or apoptosis, which is in clinical use for the treatment of advanced prostate cancer. Prostate cancer cells exposed to PSC27 WNT16B -conditioned medium compared to control medium consistently showed significant attenuation of chemotherapyinduced cytotoxicity across a range of MIT concentrations after 3 d (P < 0.05) ( Fig. 5a and Supplementary Fig. 6a ). Short-term cell viability assays confirmed that, compared to controls, PSC27 WNT16B -conditioned medium improved cancer cell survival after acute 12-h exposures to MIT (P < 0.01) (Supplementary Fig. 6b ). Apoptotic responses measured after 24 h of MIT exposure were substantially attenuated by PSC27 WNT16B -conditioned medium (P < 0.01), an effect that was blocked by treatment with XAV939 (Fig. 5b,c) . To determine whether these observations were of relevance to tumor therapy in vivo, we treated mice with tumor grafts comprised of PC3 cells plus PSC27 WNT16B or PSC27 C fibroblasts with three cycles of MIT given every other week. MIT treatment significantly reduced the tumor volumes (P < 0.001). However, grafts of tumor cells with PSC27 WNT16B fibroblasts attenuated the tumor inhibitory effects of MIT compared to tumor cells grafted with control PSC27 fibroblasts: PC3+PSC27 C and PC3+PSC27 WNT16B tumors averaged 13 mm 3 and 78 mm 3 , respectively (P < 0.001) (Fig. 5d) . Experiments using MDA-MB-231 breast cancer cells plus breast fibroblasts produced similar results (Supplementary Fig. 6c) . To evaluate the influence of WNT16B on the acute effects of chemotherapy, we examined cohorts of PC3+PSC27 C and PC3+PSC27 WNT16B xenografts 24 h after MIT treatment to quantify DNA damage using γ-H2AX immunofluorescence and apoptosis using cleaved caspase 3 immunohistochemistry (IHC). Compared to PC3+PSC27 C grafts, there was no difference in the number of DNA damage foci in PC3+PSC27 WNT16B tumors, but significantly fewer apoptotic cells were present (34% compared to 14%, respectively; P < 0.05) (Fig. 5e) .
The conditioned medium from PSC27-RAD cells, representing the full fibroblast DDSP, significantly increased the viability of PC3 cancer cells exposed to MIT concentrations ranging between 0.1-1 µM in vitro (P < 0.01) (Fig. 6a) . In comparison to PSC27-RADconditioned medium, PSC27-RAD+shRNA WNT16B or PSC27 IκBα RAD fibroblasts, engineered to suppress WNT16B expression or NF-κB activation, respectively, substantially augmented the effects of MIT, further increasing apoptosis and reducing tumor cell viability by 30-40%. Blocking β-catenin signaling in carcinoma cells with XAV939 also attenuated the effects of PSC27-RAD-conditioned medium on promoting tumor cell survival (Fig. 6b-d and Supplementary Fig. 7a,b) . This effect of WNT16B was also evident in vivo. PC3+PSC27-RAD tumor grafts averaged 300 mm 3 in size compared to 25 mm 3 for grafts of PC3 cells alone (P < 0.001). MIT chemotherapy suppressed the growth of the PC3+PSC27-RAD grafts, though residual tumors were still readily detectable and averaged 55 mm 3 in size (Fig. 6e) . However, after MIT treatment, residual tumors of PC3 cells with PSC27-RAD + shRNA WNT16B fibroblasts, with attenuated WNT16B induction, were on average ~33% smaller than PC3+PSC27-RAD tumors (P < 0.001) (Fig. 6e) . Experiments with MDA-MD-231 cells and breast fibroblasts produced similar results (Supplementary Fig. 7c ). To more accurately mimic the clinical situation of cancer therapy, we also grafted tumor cells with unirradiated PSC27 fibroblasts (PSC27 C ) and followed the same treatment schema of three MIT cycles. Tumors from mice treated with MIT were substantially smaller than tumors from untreated mice (P < 0.001). Attenuating the induction of WNT16B further enhanced the effects of chemotherapy: after MIT treatment, grafts of PC3 cells and PSC27 C + shRNA WNT16B were on average 40% smaller than grafts of PC3 cells combined with PSC27 C cells without shRNA WNT16B (P < 0.001) (Fig. 6f and Supplementary Fig. 7d ).
DISCUSSION
Optimizing radiotherapy and chemotherapy for the treatment of malignant neoplasms has relied on the iterative development and testing of models involving tumor growth dynamics, mutation rates and cell-kill kinetics. However, the most theoretically effective tumoricidal strategies must usually be tempered because of detrimental effects to the host. This reality has led to the development of regimens in which therapies are administered at intervals or cycles to avoid irreparable damage to vital host functions. However, the recovery and repopulation of tumor cells between treatment cycles is a major cause of treatment failure 15, 16 . Interestingly, rates of tumor cell repopulation have been shown to accelerate in the intervals between successive courses of treatment, and solid tumors commonly show initial responses followed by rapid regrowth and subsequent resistance to further chemotherapy. Our results indicate that damage responses in benign cells comprising the tumor microenvironment may directly contribute to enhanced tumor growth kinetics (Fig. 6g) .
The autocrine-and paracrine-acting influences of genotoxic stress responses can exert complex and potentially conflicting cell nonautonomous effects 33, 34 . Overall, our findings are in agreement with studies of DNA damage in which the execution of a signaling program culminating in a senescence phenotype is accompanied by elevated concentrations of specific extracellular proteins termed a 'senescence messaging secretome' or a 'senescence-associated secretory phenotype' 33, 34 . DNA damage responses and senescence programs can clearly operate in a cell autonomous 'intrinsic' manner to arrest cell growth and inhibit tumor progression, as has been observed in premalignant nevi 35 . Secreted factors such as insulin-like growth factor binding protein 7 (IGFBP7) and the chemokine (C-X-C motif) receptor 2 (CXCR2) ligands IL-6 and IL-8 participate in a positive feedback loop to fortify the senescence growth arrest induced by oncogenic stress and also promote immune responses that clear senescent cells and enhance tumor regression 23, 32, 36, 37 . However, in addition to proinflammatory cytokines, the damage response program comprises proteases and mitogenic growth factors, such as MMPs, hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) ligands that have clear roles in promoting tumor growth, inhibiting cellular differentiation, enhancing angiogenesis and influencing treatment resistance 19, 20, 38 . This concept is supported by reports of tissue-specific chemoresistant survival niches involving hematopoietic neoplasms, such as lymphomas 39 . The situation also has parallels with studies of radiation and chemotherapy paradoxically promoting tumor dissemination 40 .
npg Collectively, these studies support several conclusions: first, the outcomes of genotoxic exposures to any specific benign or neoplastic cell depend on the integration of innate damage response capabilities and the context that is dictated by the composition of the tumor microenvironment; second, although intrinsic drug resistance is clearly operative in some cancers, acquired resistance can also occur without alterations in intrinsic cellular chemosensitivity 41 , and our results provide strong support for previous studies that implicate constituents of the tumor microenvironment as important contributors to this resistance [42] [43] [44] ; and third, specific microenvironment DDSP proteins that promote therapy resistance such as WNT16B are attractive targets for augmenting responses to more general genotoxic therapeutics. However, the complexity of the damage response program also supports strategies that are focused on inhibiting upstream master regulators, such as NF-κB 45 , that may be more efficient and effective adjuncts to cytotoxic therapies, provided their side effects are tolerable.
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